
# RealRate

## PHARMACEUTICAL 2017

# OMEROS CORP Rank 168 of 292







#### PHARMACEUTICAL 2017

### OMEROS CORP Rank 168 of 292



The relative strengths and weaknesses of OMEROS CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OMEROS CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 59% points. The greatest weakness of OMEROS CORP is the variable Expenses, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 48% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	60,262
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,071
Liabilities, Non-Current	0
Other Assets	5,835
Other Compr. Net Income	0
Other Expenses	9,231
Other Liabilities	0
Other Net Income	-4,650
Other Revenues	41,617
Property and Equipment	1,181
Research and Development	50,699
Selling, General and Administrative Expense	43,782

Output Variable	Value in 1000 USD
Assets	67,278
Liabilities	16,071
Expenses	103,712
Revenues	41,617
Stockholders Equity	51,207
Net Income	-66,745
Comprehensive Net Income	-66,745
Economic Capital Ratio	51%

